Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

16th International Myeloma Workshop /
Promising myeloma agents in phase II trials

1st - 4th Mar 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.03.17
Views: 1465

Dr Ruben Niesvizky - New York Presbyterian Hospital-Weill Cornell Medical Center, New York, USA

Dr Niesvizky speaks with ecancer at the 16th International Myeloma Workshop about promising agents in phase II trials for the management of myeloma.

He discusses the difficulty of integrating new agents into new molecules, and the challenge that patients face when trying to select effective drugs for their treatment.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation